Research Reports | Market Assessment
November 2021

Narcolepsy – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of narcolepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of narcolepsy for each country, as well as annualized case counts projected to the national population.

Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years.

Table of contents

  • Narcolepsy - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Key Updates
      • Prevalence of Narcolepsy per 100,000 Among People of All Ages in 2022 and 2042
      • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Narcolepsy Over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalence
      • Diagnosed Incidence
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Narcolepsy
        • Studies Excluded From the Analysis of Narcolepsy
      • Risk / Protective Factors
        • Risk / Protective Factors for Narcolepsy
      • Bibliography
      • Glossary
      • Abbreviations
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H.

Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports